Corporate Governance

Long Term Incentive Programs

The purpose of long-term incentive plans is to generate the conditions for retaining and recruiting competent personnel to the Group and to offer employees an attractive opportunity to acquire a stake in the company, so as to encourage continued company loyalty by combining the interests of the shareholders and the employees.The programmes are thought to have a positive effect on the Group’s ongoing development and hence to be beneficial for shareholders and the company alike. 

Share and related incentive plans

At the annual general meeting on May 4, 2023, new articles of association were adopted whereby the A share class was deleted and series B shares were reclassified as ordinary shares. In relation to the new incentive program that was adopted at the same annual general meeting, a new issue of 970,500 C-shares has taken place during the second quarter and of these, 105,750 have been converted into ordinary shares through the transfer of 105,750 own ordinary shares to the participants in LTIP 2023.

On November 7, 2023, the board announced that it had decided to carry out a partially guaranteed new issue of shares with preferential rights for existing shareholders. The board's decision on the rights issue was approved at an extraordinary general meeting held on December 1, 2023. The final outcome of the rights issue shows that 48,664,647 ordinary shares were subscribed.

Medivir's holdings amount to 11,413 own ordinary shares and 864,750 own C shares in the company.

Warrants - At the beginning of the period, there were 1,587,000 outstanding warrants in the ongoing incentive programs. During December 2023, 527,000 warrants in the 2020 program expired. The total number of outstanding warrants at the end of the period amounted to 1,060,000.

Nomination Committee

According to an AGM resolution, the Nomination Committee 2023-2024 should consist of representatives of at least the three largest shareholders at the end of the third quarter of 2023 and the Chairman of the Board. Work on composing the Nomination Committee is now completed, and this year’s Nomination Committee consists of:

Karl Tobieson, appointed by Linc AB

Richard Torgerson, appointed by Nordea Investment Funds

Stefan Bengtsson, appointed by CA Fastigheter AB

Uli Hacksell, Chairman of the Board, Medivir AB


Corporate Governance Reports

2023  2022  2021  2020  2019   2018   2017   2016  2015   2014   2013  2012   2011   2010  2009  2008


Auditors are elected by the annual general meeting for a term of one year.

Grant Thornton Sweden AB was elected as auditors at the annual general meeting in May 2023 for the period until the annual general meeting in 2024. The main person responsible is authorized public accountant Therese Utengen.

The auditors work according to an audit plan and continuously report their observations to the audit committee and the board, partly during the course of the audit, partly in connection with the approval of the annual report.


Remuneration to senior executives

Remuneration principles for senior executives of Medivir are determined by the Annual General Meeting. The term, senior executives, refers to the CEO and other members of the management group.

The guidelines mean, in effect, that the company shall offer a competitive total remuneration package that enables the recruitment and retention of qualified senior executives.


See the profiles of our management team and Board of Directors